Clinical Trials · NCT02655237

A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids

Name: A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Gonadorelin

Phase: Phase 3
Recruitment status: Completed
Sponsor: Takeda
Enrollment: 281
Start date: Mar 2016
Locations: 25 sites, Japan
Primary endpoint: Percentage of Participants With Total PBAC Score of <10 From Week 6 to 12

View Gonadorelin compound reference